

# Franz-Josef Neumann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2836479/publications.pdf>

Version: 2024-02-01

92  
papers

31,361  
citations

87888

38  
h-index

51608

86  
g-index

94  
all docs

94  
docs citations

94  
times ranked

22187  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 518-528.	3.3	2
2	Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 747-761.	2.0	4
3	Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 1-9.	2.1	6
4	Determinants of fibrotic atrial cardiomyopathy in atrial fibrillation. A multicenter observational study of the RETAC (reseau européen de traitement des troubles du rythme cardiaques)-group. <i>Clinical Research in Cardiology</i> , 2022, 111, 1018-1027.	3.3	7
5	5-Year outcomes after transcatheter aortic valve implantation: Focus on paravalvular leakage assessed by echocardiography and hemodynamic parameters. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1582-1589.	1.7	15
6	Correlation and Relative Prognostic Value of Fractional Flow Reserve and Pd/Pa of Nonculprit Lesions in ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121010796.	3.9	2
7	Electrocardiographic diagnosis of atrial cardiomyopathy to predict atrial contractile dysfunction, thrombogenesis and adverse cardiovascular outcomes. <i>Scientific Reports</i> , 2022, 12, 576.	3.3	9
8	Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2022, Publish Ahead of Print, .	0.7	2
9	Access route and clinical outcomes after ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing invasive treatment strategy. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.8	0
10	Impact of high platelet turnover on the platelet transcriptome: Results from platelet RNA-sequencing in patients with sepsis. <i>PLoS ONE</i> , 2022, 17, e0260222.	2.5	4
11	Comparison of various late gadolinium enhancement magnetic resonance imaging methods with high-definition voltage and activation mapping for detection of atrial cardiomyopathy. <i>Europace</i> , 2022, 24, 1102-1111.	1.7	24
12	Preadmission antiplatelet therapy and treatment effect of ticagrelor versus prasugrel in patients with acute coronary syndromes - a subgroup analysis of the ISAR-REACT 5 trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	3.0	1
13	Impact of the Aortic Geometry on TAVI Prosthesis Positioning Using Self-Expanding Valves. <i>Journal of Clinical Medicine</i> , 2022, 11, 2259.	2.4	0
14	Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. <i>European Heart Journal</i> , 2022, 43, 2783-2797.	2.2	74
15	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1111-1119.	1.7	2
16	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 417-427.	2.9	19
17	Reply. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1484.	2.8	0
18	Association of Prolonged Fluoroscopy Time with Procedural Success of Percutaneous Coronary Intervention for Stable Coronary Artery Disease with and without Chronic Total Occlusion. <i>Journal of Clinical Medicine</i> , 2021, 10, 1486.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Atherectomy and Drug-Coated Balloon Angioplasty for the Treatment of Long Infrapopliteal Lesions: A Randomized Controlled Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010280.	3.9	16
20	Impact of high-sensitivity cardiac troponin T on survival and rehospitalization after transcatheter aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E881-E888.	1.7	3
21	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010565.	3.9	4
22	Non-invasive body surface electrocardiographic imaging for diagnosis of atrial cardiomyopathy. <i>Europace</i> , 2021, 23, 2010-2019.	1.7	11
23	Prognostic value of haemoglobin drop in patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13670.	3.4	3
24	Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2021, 338, 8-13.	1.7	1
25	Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes. <i>Clinica Chimica Acta</i> , 2021, 523, 106-113.	1.1	9
26	Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021, 10, e021418.	3.7	1
27	Peripheral Vascular Intervention in Patients With Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2581-2583.	2.9	0
28	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.6	0
29	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	2.2	4,210
30	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1298-1307.	1.7	12
31	Amplified sinus-P-wave reveals localization and extent of left atrial low-voltage substrate: implications for arrhythmia freedom following pulmonary vein isolation. <i>Europace</i> , 2020, 22, 240-249.	1.7	30
32	Arterial Lactate in Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2208-2216.	2.9	61
33	Evaluation of mortality following paclitaxel drug-coated stent angioplasty of femoropopliteal lesions in real world. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1306-1314.	1.7	1
34	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2020, 173, 436-444.	3.9	44
35	Ticagrelor or Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 2329-2337.	1.6	26
36	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2436-2446.	2.8	41

#	ARTICLE	IF	CITATIONS
37	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>European Heart Journal</i> , 2020, 41, 1839-1851.	2.2	106
38	Towards a lesion-specific approach to percutaneous coronary intervention for bifurcation lesions. <i>European Heart Journal</i> , 2020, 41, 2537-2540.	2.2	4
39	Accuracy of Carotid Artery Stenosis Quantification with 4-D-Supported 3-D Power-Doppler versus Color-Doppler and 2-D Blood Velocity-Based Duplex Ultrasonography. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 1082-1091.	1.5	1
40	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. <i>Circulation</i> , 2020, 141, 891-901.	1.6	28
41	The Natural History of Nonculprit Lesions in STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 954-961.	2.9	27
42	Ultrastructural, transcriptional, and functional differences between human reticulated and non-reticulated platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2034-2046.	3.8	34
43	Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial. <i>EuroIntervention</i> , 2020, 16, 225-232.	3.2	24
44	General Anesthesia or Conscious Sedation for Transfemoral Aortic Valve Replacement with the SAPIEN 3 Transcatheter Heart Valve. <i>International Heart Journal</i> , 2020, 61, 713-719.	1.0	4
45	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	2.2	4,537
46	Complex Stenting for Complex Lesions. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1938-1940.	2.9	4
47	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019, 381, 1524-1534.	27.0	543
48	Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps. <i>Blood</i> , 2019, 134, 1859-1872.	1.4	113
49	“Ten commandments” for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization. <i>European Heart Journal</i> , 2019, 40, 79-80.	2.2	330
50	The Duration of the Amplified Sinus-P-Wave Identifies Presence of Left Atrial Low Voltage Substrate and Predicts Outcome After Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 531-543.	3.2	67
51	Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. <i>American Heart Journal</i> , 2018, 200, 44-50.	2.7	111
52	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	2.2	7,100
53	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
54	Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis. <i>International Journal of Cardiology</i> , 2018, 252, 57-62.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Hemodynamic classification of paravalvular leakage after transcatheter aortic valve implantation compared with angiographic or echocardiographic classification for prediction of 1-year mortality. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, E56-E63.	1.7	7
56	Uncontrolled Diabetes Mellitus Has No Major Influence on the Platelet Transcriptome. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	6
57	The Transcription Factor ETV1 Induces Atrial Remodeling and Arrhythmia. <i>Circulation Research</i> , 2018, 123, 550-563.	4.5	40
58	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2018, 392, 940-949.	13.7	555
59	Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. <i>American Heart Journal</i> , 2018, 205, 77-86.	2.7	6
60	Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 376, 1234-1244.	27.0	549
61	Valve Thrombosis after TAVI. <i>European Heart Journal</i> , 2017, 38, 2700-2701.	2.2	9
62	Hypo-attenuated leaflet thickening of transcatheter aortic valves: jeopardy or epiphenomenon?. <i>European Heart Journal</i> , 2017, 38, 1218-1221.	2.2	2
63	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1607-1617.	2.9	29
64	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. <i>Lancet, The</i> , 2017, 390, 1747-1757.	13.7	443
65	Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 1030-1041.	3.3	22
66	Comparison of Immature Platelet Count to Established Predictors of Platelet Reactivity During Thienopyridine Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 286-293.	2.8	57
67	Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial. <i>European Heart Journal</i> , 2016, 37, 3399-3405.	2.2	62
68	Discordant cardiac biomarker levels independently predict outcome in ST-segment elevation myocardial infarction. <i>Clinical Research in Cardiology</i> , 2016, 105, 432-440.	3.3	12
69	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. <i>European Heart Journal</i> , 2016, 37, 1538.1-1549.	2.2	147
70	Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents. <i>Clinical Research in Cardiology</i> , 2016, 105, 230-238.	3.3	15
71	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015, 36, 1252-1263.	2.2	366
72	Stent Placement vs. Balloon Angioplasty for Popliteal Artery Treatment. <i>Journal of Endovascular Therapy</i> , 2015, 22, 22-27.	1.5	46

#	ARTICLE	IF	CITATIONS
73	Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1503.	7.4	580
74	Purulent pericarditis and pneumonia caused by <i>Streptococcus equi</i> subsp. <i>zooepidemicus</i> . <i>Journal of Medical Microbiology</i> , 2014, 63, 313-316.	1.8	13
75	Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions. <i>Journal of Invasive Cardiology</i> , 2014, 26, 630-8.	0.4	7
76	Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: Platelet reactivity in an observational study. <i>Platelets</i> , 2013, 24, 549-553.	2.3	16
77	Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1424-1431.	1.6	207
78	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2159-2164.	2.8	569
79	Sirolimus-Eluting Stents for Treatment of Infrapopliteal Arteries Reduce Clinical Event Rate Compared to Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2012, 60, 587-591.	2.8	152
80	Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. <i>European Heart Journal</i> , 2011, 32, 2274-2281.	2.2	162
81	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 2482-2491.	2.2	82
82	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.	2.2	2,649
83	Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1925-1934.	2.8	523
84	Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. <i>Circulation</i> , 2007, 116, 2923-2932.	1.6	831
85	Two-Year Results after Directional Atherectomy of Infrapopliteal Arteries with the SilverHawk Device. <i>Journal of Endovascular Therapy</i> , 2007, 14, 232-240.	1.5	83
86	Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention. <i>Circulation</i> , 2005, 111, 2560-2564.	1.6	363
87	Midterm Results after Atherectomy-assisted Angioplasty of Below-Knee Arteries with Use of the Silverhawk Device. <i>Journal of Vascular and Interventional Radiology</i> , 2004, 15, 1391-1397.	0.5	74
88	Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban. <i>New England Journal of Medicine</i> , 2001, 344, 1879-1887.	27.0	1,918
89	Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2000, 35, 915-921.	2.8	334
90	Operator volume and outcome of patients undergoing coronary stent placement. <i>Journal of the American College of Cardiology</i> , 1998, 32, 970-976.	2.8	73

#	ARTICLE	IF	CITATIONS
91	Cardiac Release of Cytokines and Inflammatory Responses in Acute Myocardial Infarction. Circulation, 1995, 92, 748-755.	1.6	410
92	Koronare Herzkrankheit: Aktuelle Aspekte der Behandlung. , 0, , .		0